Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch

Nature Biotechnology 2026

View at publisher

Authors: C A Sheridan

DOI: 10.1038/s41587-025-02987-0

Cited by: 14

Fields of Study & Subjects

Muscle Physiology and Disorders Genetic Neurodegenerative Diseases Cardiomyopathy and Myosin Studies